RxDoctor Payments Data

Daniel Braschayko

Family · Sterling Heights, MINPI 1003587759

Payments from drug & device makers

$7,140in general payments, 2019–2025

Across 460 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$851
  • Amgen$767
  • Lilly USA, LLC$549
  • Pfizer$512
  • Otsuka America Pharmaceutical, Inc.$351
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,134100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,140 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$30,915
Medicare patients
141
Services billed
314

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin104$84,904
EliquisApixaban59$65,298
OzempicSemaglutide31$55,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$44,647
FarxigaDapagliflozin Propanediol33$34,052
TrulicityDulaglutide25$30,924
XareltoRivaroxaban15$23,895
JanuviaSitagliptin Phosphate20$18,783
EntrestoSacubitril/Valsartan13$17,804
GemtesaVibegron36$16,125
ZenpepLipase/Protease/Amylase13$11,982
MyrbetriqMirabegron12$10,055
Lagevrio (Eua)Molnupiravir14$6,746
Humalog Kwikpen U-100Insulin Lispro21$5,708
Tresiba Flextouch U-100Insulin Degludec11$5,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$237$84,904104 claims
PfizerEliquis$512$65,29859 claims
Novo NordiskOzempic$1,150$55,94131 claims
GSKTrelegy Ellipta$98$44,64735 claims
AstraZenecaFarxiga$305$34,05233 claims
Lilly USA, LLCTrulicity$549$30,92425 claims
MerckJanuvia, Lagevrio (Eua)$188$25,52934 claims
Johnson & JohnsonXarelto$91$23,89515 claims
NovartisEntresto$327$17,80413 claims
Sumitomo Pharma America, Inc.Gemtesa$88$16,12536 claims
Aimmune Therapeutics, Inc.Zenpep$15$11,98213 claims
Astellas Pharma US IncMyrbetriq$31$10,05512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Sterling Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →